WilmerHale Advises Spark Therapeutics in Public Offering

WilmerHale Advises Spark Therapeutics in Public Offering

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

WilmerHale’s lawyers are renowned for their work on mergers and acquisitions, IPOs, private equity deals, strategic alliances and corporate governance matters both domestically and in the EU and China. Healthcare clients, which include Medtronic and PerkinElmer, know us as a one-stop source for solutions to the diverse array of corporate issues they face.

For clients that range from public and private companies to individual entrepreneurs, our corporate lawyers have:

  • Served as issuer counsel or underwriters’ counsel in more than 400 public offerings and Rule 144A placements raising nearly $150 billion since 2006. We have a wide array of capital markets experience, as well as significant commercial finance knowledge.
  • Advised on more than 1,000 M&A deals with a total value in excess of $400 billion since 2006. Our experience ranges from public-public mergers and related SEC, disclosure and fiduciary duty issues to the unique issues presented by sales of private equity and venture-backed private companies.
  • Handled hundreds of strategic alliances, joint ventures, outsourcing and licensing transactions each year, including several strategic alliances that have received industry recognition for their importance. The complexity of these deals often demands deep experience and close collaboration among our corporate, licensing, intellectual property and tax lawyers, as well as our lawyers in the United States, Europe and Asia.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Spark Therapeutics, Inc. announced the closing of an underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission. The aggregate net proceeds to Spark in the offering were approximately $128 million, after deducting underwriting discounts and before offering expenses.

Spark, a fully-integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark's validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases; liver-associated diseases, such as hemophilia; and neurodegenerative diseases.

The WilmerHale team on the transaction was led by Partner Lia Der Marderosian and included Senior Associate Ryan Mitteness and Associate John Wagner.

For more information, read Spark's press release.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel